1232 results about "Drug treatment" patented technology

The invention relates to the extraction and/or presentation of glucose concentrations estimated as a function of time into a format that facilitates conveyance of the underlying information. More particularly, short term actions, such as exercise, diabetes drug treatment, and/or food intake, are correlated to glucose response profiles. Optionally, glucose concentration responses are back correlated to parameters, such as time, exercise, diabetes drug treatment and/or food intake. The resulting correlated data are output to the user in a time compressed format, in video format, and/or as a cluster allowing diagnosis and treatment information to be more readily determined and used. These information presentations are useful for both the medical professional and the end user. The information presentation is preferably used with a noninvasive, implantable, semi-continuous, and/or continuous analyte analyzer, such as a glucose concentration analyzer.

Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.

Disclosed is an extended or controlled release dosage form of citalopram or its related forms and other newer antidepressants for oral administration to treat chronic patients suffering from depression and to minimize the side effects associated with the current drug treatment.

An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications.

An efficient, objective testing method and system for evaluating changes in mental function is described. The method and system are based on measuring an individual's behavioral responses and brain function during a brief cognitive test battery and passive control conditions. The method and system is designed to assess an individual's fundamental cognitive functions, and whether those functions have been significantly affected by a variety of factors such as progressive disease processes, medication, stress, fatigue, training, or the passage of time. The method and system can be used to determine whether drugs being evaluated to treat diseases or conditions affecting cognitive brain function have a significant positive effect on delaying or improving the symptoms of such a disease or condition, especially during clinical trials for drug approval and subsequent marketing. The method and system may also be employed as part of the successful diagnosis or ongoing treatment of neurological diseases or conditions that directly or indirectly affect human neurocognitive performance. The method and system may also be used to determine transitory changes in overall cognitive function due to emotional stress or fatigue, and more long lasting changes in overall cognitive function following training and educational programs.

The present disclosure generally pertains to systems and methods for drug compliance monitoring. A drug compliance monitoring system in accordance with one exemplary embodiment of the present disclosure comprises a portable drug containment unit, which has a drug container, such as a pill bottle, for holding prescription or non-prescription drugs. The drug containment unit also comprises at least one sensor and control logic. The sensor is configured to automatically sense a parameter indicating when a drug, such as one or more pills or an amount of liquid, has been or is about to be removed from the drug container. The system, based on the sensor, automatically estimates and tracks drug consumption and provides a patient with reminders when a dosage is currently due. If the patient deviates from an expected drug regime, the system automatically senses this event and provides a notification to the patient or caregiver. In addition, the system stores a usage history indicating the approximate time and amount of each sensed dosage.

Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.

Real-time and individualized disease monitoring is central to rapidly evolving medical sciences and technologies, but for the vast majority of patients, disease progression and treatment are monitored only in an irregular and discontinuous fashion. Consequently, disease progression and relapse are often allowed to proceed too far before they are detected, compromising the possibility of any effective treatment. For one patient, this can mean becoming refractory to the few early drug treatments that are available; for another, missing early detection may be deadly. This invention provides a method for the detection of early signals of disease and recovery thereof comprising a universal yet personalized health-monitoring solution using cell phones or other wearable smart device data that generate extensive real-time data. The invention further provides a system and method to provide answers to a variety of questions related to the patient health status and health trajectory. Its flexibility and generality is designed for a preferred application to rare disorders and rare questions for which other analytical system are lacking.

The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.

This invention provides methods for detecting and predicting drug interaction. In one embodiment of the invention, a plurality of cellular constituents in a biological sample is monitored as the sample is subject to various drug treatments. The response of the cellular constituents are analyzed to detect interactions. This method is particularly useful for predicting drug interaction using a model organism. It is also useful for analyzing interaction between any perturbations to a biological system.

A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The used syringe is sent back in the pig to the radiopharmacy for disposal. The pig includes a cap that is removably attached to a base. Shielding elements, typically formed from lead, are enclosed in the cap and the base. The pig can be used to transport a conventional syringe or a safety syringe. The pig can be used with or without an inner liner in the base. There is never an inner liner in the cap.

The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.

A system for monitoring compliance with a medication regimen comprises a patch. The patch includes an RFID apparatus and a sensor. The patch is configured to be removably securable to a body of a biological organism. The sensor is in electrical communication with the RFID apparatus and is configured to inspect a biological material of a biological organism for the presence of a detectable agent. The RFID apparatus is configured to communicate a result of the inspection to an RFID transceiver and/or a communication device. Methods are also provided.

A minimally invasive method of performing mitral annuloplasty is disclosed. An implantable device is positioned within the coronary sinus and tightened around the mitral annulus. Mitral valve regurgitation is monitored before, during, and/or after the tightening step. An on-going drug therapy may be determined, taking into account post-implantation hemodynamic function.

The present invention provides methods for enhanced detection of biological response profiles. In particular, the methods of this invention allow for the detection of biological response patterns, such as gene expression patterns, in response to different drug treatments. The methods of the invention also allow the determination of a "consensus profile" which describes a particular class or type of biological response. In certain embodiments the consensus profile may describe the biological response of a particular group or class of drugs. In other embodiments, the consensus profile may describe an "ideal" biological response such as one associated with a desired therapeutic effect. The methods of the present invention also allow for the comparison of different biological responses. Thus, the methods of the invention may be used, e.g., to identify and/or study new drugs.

A method for treating a patient using an antidiabetic drug, said method comprising administering to the patient a high dose of the antidiabetic drug wherein said antidiabetic drug exhibits one or more dose proportional pharmacokinetic parameters is described.

The invention discloses an artificial intelligence auxiliary diagnosis and treatment system and a construction method thereof, equipment and a storage medium and belongs to the technical field of lifehealth. The system includes a disease knowledge map module, a disease diagnosis model module and a machine learning decision module, wherein the disease knowledge map module is configured to collectvarious resources about diseases and form a disease knowledge database for querying and reading, the disease diagnosis model module is configured to receive the patient information, store the information in the system database, input the information to the machine learning decision module, extract indicator data from the disease knowledge map module through the machine learning decision module toperform comparative analysis, push a patient information set and suggest an examination which a patient needs to take and a scheme set of related drug treatment for choose of doctors. The system is advantaged in that the underlying knowledge map is comprehensive and authoritative, interaction operation is simple, use efficiency is high, on the human-computer interaction level, the intelligence degree is high.

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

An improved diagnostic analyte monitoring device has immovable, rigid sensors connected stationarily to control and measuring means and a flexible surface adhering to the skin and serving for the subcutaneous implantation of the sensors, actuated by means designed for easy handling. Concentrationtime profiles of endogenous and exogenous analytes measured with the device are used to improve drug treatment modalities on an individualized basis.

In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of diffuse-type gastric cancer. As a result, in-frame fusion transcripts between the CEP55 gene and the RET gene were identified. It was also found that said gene fusions induce activation of RET protein, thereby causing canceration of cells. Further, it was demonstrated that the RET protein activation and canceration caused by said gene fusion can be suppressed by using a RET tyrosine kinase inhibitor, and that treatments with a RET tyrosine kinase inhibitor are effective in patients with detection of said gene fusion.

A system is provided that integrates of records of clinical laboratory services into the assessment and optimization of patient health care and, in particular, regulation of the use of pharmaceuticals. Laboratory test result records are used in conjunction with other health care benefits records to monitor regulation of use of pharmaceuticals by patients. The incorporation of laboratory tests and results into such a utilization system allows improvement in the management of a patient's therapy based on a more precise picture of the patient's level of illness as revealed by the laboratory test results. The system of the present invention also allows optimization of the selection of laboratory tests to be performed, and also provides an outcome assessment of the risk of hospitalization due to pharmaceutical treatments resulting in physician intervention, leading to a change in physician prescribing behavior and, accordingly, a decrease in drug induced hospitalizations and improved quality of patient care and savings of health care costs.